TY - JOUR
T1 - Viewpoints
T2 - Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye
AU - Koh, Gou Young
AU - Augustin, Hellmut G.
AU - Campochiaro, Peter A.
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/5
Y1 - 2022/5
N2 - Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.
AB - Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85127502196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127502196&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2022.03.004
DO - 10.1016/j.molmed.2022.03.004
M3 - Short survey
C2 - 35396185
AN - SCOPUS:85127502196
SN - 1471-4914
VL - 28
SP - 347
EP - 349
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 5
ER -